VKTX 241206 47.00P (VKTX241206P47000) Stock Options, News & Quotes

US OptionsDetailed Quotes

VKTX241206P47000

Watchlist

0.18
-0.22-55.00%

15min DelayClose Nov 29 12:59 ET

0.18High0.17Low

Intraday

5D
Daily

News

Piper Sandler Initiates Coverage On Viking Therapeutics With Overweight Rating, Announces Price Target of $74
Benzinga05:48 ET · Ratings
Piper Sandler Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $74
Moomoo News05:34 ET · Ratings
Express News | Viking Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $74
Reuters04:16 ET
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
BenzingaNov 29 08:42 ET
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow
Yahoo FinanceNov 28 13:17 ET
Will weight loss drugs be included in the US medical insurance, becoming the strongest "roadblock" for the Trump team?
The "Dual Weight Loss Champions" led the significant rise.
Gelonghui FinanceNov 26 20:45 ET

Comments

Shaaaw

Nov 27 06:52

Today, $Amgen (AMGN.US)$ announced the P2 trial results for MariTide, which only include the safety profile for the 420 mg dose escalation cohorts (cherry-picking at it's finest again).
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...